Nanobac Introduces New Improved ELISA Kits -- MEDICA - World Forum for Medicine


Nanobac Oy

Nanobac Introduces New Improved ELISA Kits

Tampa, Fla. (October 26, 2005) - Nanobac Life Sciences, Inc. (OTCBB: NNBP) (“Nanobac” or “the Company”) announced today the introduction of two new versions of its NANOCAPTURE™ and NANO-SERO™ ELISA test kits for the detection of Calcifying Nano-Particles (CNPs), also known as nanobacteria, in serum or plasma. The new kits offer improved sensitivity, lower background and improved stability over the previous versions. Nanobac has added new standards to improve precision at the low end and freeze dried the critical components for improved stability.
“Our demand for CNP diagnostic products is increasing as CNP’s or nanobacteria are implicated in more and more chronic diseases,” stated Grant Carlson, Nanobac’s President and Chief Operating Officer. “Nanobac has worked hard to develop robust, sensitive and reproducible ELISA test kits for the CNP/nanobacteria research community. These kits are CE marked and ready for immediate shipment throughout the European Union. In the United States the kits will be sold For Research Use Only (RUO).”
The NANOCAPTURE ELISA is a two-site immunoenzymatic assay for the quantitative measurement of CNP/nanobacterial antigen in serum or plasma. The NANO-SERO ELISA is also a two site immunoenzymatic assay for the quantitative measurement of anti-CNP antibodies in serum or plasma. Nanobac will feature the NANOCAPTURE and NANO-SERO ELISA test kits at the world’s #1 medical trade show, MEDICA, in Dusseldorf, Germany, November 16-19, 2005. Last year the show attracted 136,000 visitors from around the world. Nanobac intends to meet with potential customers and establish its global network of in vitro diagnostic distributors.
About Nanobac Life Sciences
Nanobac Life Sciences, Inc. is a broad-based life science company that discovers, develops, manufactures, and markets a range of products and services to improve people’s health through the detection and treatment of Calcifying Nano-Particles, otherwise known as “nanobacteria”. The Company’s pioneering research is establishing the pathogenic role of nanobacteria in soft tissue calcification, particularly in coronary artery heart disease, prostatitis and vascular disease.

Nanobac manufactures and markets In Vitro Diagnostic (IVD) kits and reagents for the detection of Calcifying Nano-Particles. IVD products include the NANOCAPTURE™ and NANO-SERO™ ELISA assays and the Nano-Vision™ line of antibodies and reagents. Nanobac’s BioAnalytical Services works with biopharmaceutical partners to develop and apply methods for avoiding, detecting, and inactivating or eliminating CNPs from raw materials. Nanobac’s Drug Discovery and Development efforts are focused on developing new and existing compounds that effectively inhibit, destroy or neutralize CNPs. The Company also markets Dietary Supplements through its subsidiary, Nanobac Sciences, LLC.

Nanobac Life Sciences, Inc. is headquartered in Tampa, Florida. For more information, please visit our website at: